Sanofi India Q3 2026: Revenue Rs 491.7 crore, PAT Rs 116.7 crore
Sanofi India standalone Q3 2026 revenue was Rs 491.70 cr and profit after tax was Rs 116.70 cr, versus Rs 475.40 cr and Rs 76.00 cr a year earlier.
Key takeaways
- Revenue from Operations Q3 2026 was Rs 491.70 cr vs Rs 475.40 cr in Q3 2025.
- Total Income Q3 2026 was Rs 497.20 cr compared with Rs 480.30 cr a year earlier.
- Profit before tax Q3 2026 was Rs 157.70 cr vs Rs 102.30 cr in Q3 2025.
- PAT Q3 2026 was Rs 116.70 cr compared with Rs 76.00 cr in Q3 2025.
- EPS (basic and diluted) for Q3 2026 was Rs 50.67 vs Rs 32.99 in Q3 2025.
Q3 2026 · standalone
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 491.70 cr | Rs 475.40 cr | +3.4% |
| PAT | Rs 116.70 cr | Rs 76.00 cr | +53.6% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
- Net margin was 23.73% of revenue, up 774 bps from 15.99%.
- Revenue rose 3.4% while total expenses fell 3.2%.
- Purchases of stock-in-trade took 46.2% of revenue, against 56.8% a year earlier.
• Basis: Standalone statement of unaudited financial results for the quarter ended 30.09.2026, compared with quarter ended 30.09.2025 (statement of financial results).
• Revenue from Operations (quarter ended 30.09.2026): Rs 491.70 cr
Revenue from Operations (quarter ended 30.09.2025): Rs 475.40 cr
• Other Income (quarter ended 30.09.2026): Rs 5.50 cr
Other Income (quarter ended 30.09.2025): Rs 4.90 cr
• Total Income (quarter ended 30.09.2026): Rs 497.20 cr
Total Income (quarter ended 30.09.2025): Rs 480.30 cr
• Total Expenses (quarter ended 30.09.2026): Rs 339.50 cr
Total Expenses (quarter ended 30.09.2025): Rs 350.70 cr
• Cost of Materials Consumed (quarter ended 30.09.2026): Rs 73.60 cr
Cost of Materials Consumed (quarter ended 30.09.2025): Rs 53.30 cr
• Purchases of stock-in-trade (quarter ended 30.09.2026): Rs 227.40 cr
Purchases of stock-in-trade (quarter ended 30.09.2025): Rs 269.80 cr
• Changes in Inventories of work-in-progress, stock-in-trade and finished goods (quarter ended 30.09.2026): Rs (63.00) cr
Changes in Inventories of work-in-progress, stock-in-trade and finished goods (quarter ended 30.09.2025): Rs (83.20) cr
• Employee benefits expense (quarter ended 30.09.2026): Rs 39.70 cr
Employee benefits expense (quarter ended 30.09.2025): Rs 41.90 cr
• Finance costs (quarter ended 30.09.2026): Rs 0.20 cr
Finance costs (quarter ended 30.09.2025): Rs 0.40 cr
• Depreciation and amortisation expense (quarter ended 30.09.2026): Rs 8.80 cr
Depreciation and amortisation expense (quarter ended 30.09.2025): Rs 9.10 cr
• Other expenses (quarter ended 30.09.2026): Rs 52.80 cr
Other expenses (quarter ended 30.09.2025): Rs 59.40 cr
• Profit before exceptional item and tax (quarter ended 30.09.2026): Rs 157.70 cr
Profit before exceptional item and tax (quarter ended 30.09.2025): Rs 129.60 cr
• Exceptional item (quarter ended 30.09.2026): Rs - million
Exceptional item (quarter ended 30.09.2025): Rs (27.30) cr
• Profit before tax (quarter ended 30.09.2026): Rs 157.70 cr
Profit before tax (quarter ended 30.09.2025): Rs 102.30 cr
• Profit for the period / year (Profit after tax) (quarter ended 30.09.2026): Rs 116.70 cr
Profit for the period / year (Profit after tax) (quarter ended 30.09.2025): Rs 76.00 cr
• Basic and diluted earnings per share (not annualised) (quarter ended 30.09.2026): Rs 50.67
Basic and diluted earnings per share (not annualised) (quarter ended 30.09.2025): Rs 32.99
According to the statement of unaudited financial results, Sanofi India’s standalone Revenue from Operations for the quarter ended 30.09.2026 was Rs 491.70 cr, compared with Rs 475.40 cr in the corresponding quarter ended 30.09.2025. Total Income for the quarter ended 30.09.2026 was Rs 497.20 cr versus Rs 480.30 cr a year earlier. Total Expenses declined to Rs 339.50 cr in the quarter ended 30.09.2026 from Rs 350.70 cr in the quarter ended 30.09.2025.
Profit before exceptional item and tax for the quarter ended 30.09.2026 was Rs 157.70 cr, compared with Rs 129.60 cr in the quarter ended 30.09.2025. After an exceptional item of Rs - million in the current quarter and Rs (27.30) cr in the corresponding quarter, Profit before tax was Rs 157.70 cr versus Rs 102.30 cr. Profit for the period / year (Profit after tax) rose to Rs 116.70 cr for the quarter ended 30.09.2026 from Rs 76.00 cr a year earlier. Basic and diluted earnings per share (not annualised) increased to Rs 50.67 in the quarter ended 30.09.2026 from Rs 32.99 in the quarter ended 30.09.2025, as per the statement of financial results.
Track Sanofi India Ltd
Cruxal reads every Sanofi India Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.
